Supernus Pharmaceuticals

(NASDAQ) SUPN

Current Price$52.26

Market Cap$2.96B

Since IPO (2012)+858%

5 Year+75%

1 Year+59%

1 Month+2%

Supernus Pharmaceuticals Financials at a Glance

Market Cap

$2.96B

Revenue (TTM)

$776.83M

Net Income (TTM)

$29.02M

EPS (TTM)

$-0.68

P/E Ratio

-75.23

Dividend

$0.00

Beta (Volatility)

0.63 (Low)

Dividend

$0.00

Beta (Volatility)

0.63 (Low)

Price

$52.26

Volume

33,387

Open

$51.45

Price

$52.26

Volume

33,387

Open

$51.45

Previous Close

$52.26

Daily Range

$50.73 - $52.47

52-Week Range

$30.44 - $59.68

Dividend

$0.00

Beta (Volatility)

0.63 (Low)

Price

$52.26

Volume

33,387

Open

$51.45

Previous Close

$52.26

Daily Range

$50.73 - $52.47

52-Week Range

$30.44 - $59.68

SUPN News

No articles available.

SUPN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Supernus Pharmaceuticals

Industry

Pharmaceuticals

Sector

Health Care

Employees

778

CEO

Jack A. Khattar, MBA

Website

www.supernus.com

Headquarters

Rockville, MD 20850, US

SUPN Financials

Key Financial Metrics (TTM)

Gross Margin

86%

Operating Margin

-5%

Net Income Margin

-4%

Return on Equity

-4%

Return on Capital

-4%

Return on Assets

-2%

Earnings Yield

-1.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.96B

Shares Outstanding

57.58M

Volume

33.39K

Avg. Volume

719.80K

Financials (TTM)

Gross Profit

$644.39M

Operating Income

$36.86M

EBITDA

$42.53M

Operating Cash Flow

$47.33M

Capital Expenditure

$1.34M

Free Cash Flow

$45.99M

Cash & ST Invst.

$308.67M

Total Debt

$40.98M

Supernus Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$207.71M

+38.6%

Gross Profit

$184.31M

+37.5%

Gross Margin

88.74%

N/A

Market Cap

$2.96B

N/A

Market Cap/Employee

$4.40M

N/A

Employees

674

N/A

Net Income

$2.29M

+80.6%

EBITDA

$8.33M

-146.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$353.97M

-17.9%

Accounts Receivable

$182.18M

+25.1%

Inventory

$87.06M

+76.2%

Long Term Debt

$30.27M

+14.8%

Short Term Debt

$0.00

-100.0%

Return on Assets

-1.93%

N/A

Return on Invested Capital

-3.78%

N/A

Free Cash Flow

$66.52M

+119.8%

Operating Cash Flow

$66.52M

+117.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7339.78-0.00%

^DJIDJI

^DJIDJI$49639.86-0.01%

^IXICNASDAQ

^IXICNASDAQ$25826.30-0.00%

BTCBitcoin

BTCBitcoin$80138.00-0.02%

AAPLAAPL

AAPLAAPL$288.76+0.00%

AMZNAMZN

AMZNAMZN$272.73-0.01%

GOOGGOOG

GOOGGOOG$394.42-0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$14.47+0.07%

INTCIntel

INTCIntel$109.62-0.03%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$71.34-0.00%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.18+0.02%

IRENIren

IRENIren$56.85-0.07%

ATRAAtara Biotherapeutics

ATRAAtara Biotherapeutics$9.93+0.93%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$45.73+0.00%

Questions About SUPN

What is the current price of Supernus Pharmaceuticals?

Supernus Pharmaceuticals is trading at $52.26 per share.

What is the 52-week range for Supernus Pharmaceuticals?

Over the past 52 weeks, Supernus Pharmaceuticals has traded between $30.44 and $59.68.

How much debt does Supernus Pharmaceuticals have?

As of the most recent reporting period, Supernus Pharmaceuticals reported total debt of $40.90M.

How much cash does Supernus Pharmaceuticals have on hand?

Supernus Pharmaceuticals reported $184.87M in cash and cash equivalents in its most recent financial results.

What is Supernus Pharmaceuticals’s dividend yield?

Supernus Pharmaceuticals does not currently have a dividend yield.

Supernus Pharmaceuticals

Supernus Pharmaceuticals Financials at a Glance

SUPN News

SUPN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Supernus Pharmaceuticals

SUPN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Supernus Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About SUPN

What is the current price of Supernus Pharmaceuticals?

What is the 52-week range for Supernus Pharmaceuticals?

How much debt does Supernus Pharmaceuticals have?

How much cash does Supernus Pharmaceuticals have on hand?

What is Supernus Pharmaceuticals’s dividend yield?

Premium Investing Services